Interplay between NF-κB/interferon signaling and the genome replication of HPV

Future Virology

Volumn 11, Issue 2, 2016, Pages 141-155

  Nakahara, Tomomi ^a   Kiyono, Tohru ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

HPV; NF B; Replication

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTOKINE; DAXX PROTEIN; DEATH RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR; ND10 PROTEIN; NUCLEAR PROTEIN; PATTERN RECOGNITION RECEPTOR; STAT PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS DNA;

BASAL CELL; CELL DIFFERENTIATION; DNA DAMAGE RESPONSE; DNA REPAIR; DNA SYNTHESIS; EPISOME; GENE CONTROL; GENE EXPRESSION; GENOTOXICITY; HOMOLOGOUS RECOMBINATION; HUMAN; KERATINOCYTE; LIFE CYCLE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; U2OS CELL LINE; UTERINE CERVIX CANCER; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN; WART VIRUS;

EID: 85015338992     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.16.2     Document Type: Review

References (80)

1. PaVE: The papillomavirus knowledge source. http://pave.niaid.nih.gov.
2. Doorbar J, Quint W, Banks L et al. The biology and life-cycle of human papillomaviruses. Vaccine 30, F55-F70 (2012).
3. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat. Rev. Cancer 14(6), 395-405 (2014).
4. Herfs M, Yamamoto Y, Laury A et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl Acad. Sci. USA 109(26), 10516-10521 (2012).
5. Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr. Prob. Dermatol. 45, 58-74 (2014).
6. Hibma MH. The immune response to papillomavirus during infection persistence and regression. Open Virol. J. 6, 241-248 (2012).
7. Nakahara T, Kiyono T. Regulation of human papillomavirus (HPV) genome replication in the viral life cycle and its association with the viral persistence and cancer development. Uirusu 64(1), 57-66 (2014).
8. Hsu YC, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. Nat. Med. 20(8), 847-856 (2014).
9. Johansson C, Schwartz S. Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat. Rev. Microbiol. 11(4), 239-251 (2013).
10. Bernard HU. Regulatory elements in the viral genome. Virology 445(1-2), 197-204 (2013).
11. Mckinney CC, Hussmann KL, Mcbride AA. The role of the DNA damage response throughout the papillomavirus life cycle. Viruses 7(5), 2450-2469 (2015).
12. Wallace NA, Galloway DA. Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses. Semin. Cancer Biol. 26, 30-42 (2014).
13. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 5(4), e1000397 (2009).
14. Bergvall M, Melendy T, Archambault J. The E1 proteins. Virology 445(1-2), 35-56 (2013).
15. Mcbride AA. The papillomavirus E2 proteins. Virology 445(1-2), 57-79 (2013).
16. Day PM, Schelhaas M. Concepts of papillomavirus entry into host cells. Curr. Opin. Virol. 4, 24-31 (2014).
17. Egawa N, Nakahara T, Ohno S-I et al. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J. Virol. 86(6), 3276-3283 (2012).
18. Hubert WG, Kanaya T, Laimins LA. DNA replication of human papillomavirus type 31 is modulated by elements of the upstream regulatory region that lie 5 of the minimal origin. J. Virol. 73(3), 1835-1845 (1999).
19. Reinson T, Henno L, Toots M, Ustav M Jr, Ustav M. The cell cycle timing of human papillomavirus DNA replication. PLoS ONE 10(7), e0131675 (2015).
20. Stubenrauch F, Hummel M, Iftner T, Laimins LA. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J. Virol. 74(3), 1178-1186 (2000).
21. Lace MJ, Anson JR, Thomas GS, Turek LP, Haugen TH. The E8-E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes. J. Virol. 82(21), 10841-10853 (2008).
22. Fisher C. Recent insights into the control of human papillomavirus (HPV) genome stability, loss, and degradation. J. Clin. Med. 4(2), 204-230 (2015).
23. Mcbride AA, Sakakibara N, Stepp WH, Jang MK. Hitchhiking on host chromatin: how papillomaviruses persist. Biochim. Biophys. Acta 1819(7), 820-825 (2012).
24. Wilson VG. The role of ubiquitin and ubiquitin-like modification systems in papillomavirus biology. Viruses 6(9), 3584-3611 (2014).
25. Fradet-Turcotte A, Moody C, Laimins LA, Archambault J. Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance. J. Virol. 84(22), 11747-11760 (2010).
26. Fradet-Turcotte A, Bergeron-Labrecque F, Moody CA, Lehoux M, Laimins LA, Archambault J. Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATM-dependent DNA damage response. J. Virol. 85(17), 8996-9012 (2011).
27. Sakakibara N, Mitra R, Mcbride AA. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J. Virol. 85(17), 8981-8995 (2011).
28. Reinson T, Toots M, Kadaja M et al. Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J. Virol. 87(2), 951-964 (2013).
29. Kim K, Lambert PF. E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology 293(1), 10-14 (2002).
30. Hammerschmidt W, Sugden B. Replication of Epstein-Barr viral DNA. Cold Spring Harb. Perspect. Biol. 5(1), a013029 (2013).
31. Hoffmann R, Hirt B, Bechtold V, Beard P, Raj K. Different modes of human papillomavirus DNA replication during maintenance. J. Virol. 80(9), 4431-4439 (2006).
32. Kanginakudru S, Desmet M, Thomas Y, Morgan IM, Androphy EJ. Levels of the E2 interacting protein TopBP1 modulate papillomavirus maintenance stage replication. Virology 478 135-142 (2015).
33. Lorenz LD, Rivera Cardona J, Lambert PF. Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6. PLoS Pathog. 9(10), e1003717 (2013).
34. Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT. HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. Proc. Natl Acad. Sci. USA 110(19), 7542-7549 (2013).
35. Maglennon GA, Mcintosh P, Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414(2), 153-163 (2011).
36. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 5(10), e1000605 (2009).
37. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl Acad. Sci. USA 104(49), 19541-19546 (2007).
38. Morin G, Fradet-Turcotte A, Di Lello P, Bergeron-Labrecque F, Omichinski JG, Archambault J. A conserved amphipathic helix in the N-Terminal regulatory region of the papillomavirus E1 helicase is required for efficient viral DNA replication. J. Virol. 85(11), 5287-5300 (2011).
39. Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair 9(12), 1299-1306 (2010).
40. Anacker DC, Gautam D, Gillespie KA, Chappell WH, Moody CA. Productive replication of human papillomavirus 31 requires DNA repair factor Nbs1. J. Virol. 88(15), 8528-8544 (2014).
41. Sakakibara N, Chen D, Jang MK et al. Brd4 is displaced from HPV replication factories as they expand and amplify viral DNA. PLoS Pathog. 9(11), e1003777 (2013).
42. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71(10), 7167-7179 (1997).
43. Weller SK, Coen DM. Herpes simplex viruses: mechanisms of DNA replication. Cold Spring Harb. Perspect. Biol. 4(9), a013011 (2012).
44. Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Ann. Rev. Biophys. 42, 443-468 (2013).
45. Shih VF, Tsui R, Caldwell A, Hoffmann A. A single NFkappaB system for both canonical and non-canonical signaling. Cell Res. 21(1), 86-102 (2011).
46. Kawamura T, Ogawa Y, Aoki R, Shimada S. Innate and intrinsic antiviral immunity in skin. J. Dermatol. Sci. 75(3), 159-166 (2014).
47. Karim R, Tummers B, Meyers C et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog. 9(5), e1003384 (2013).
48. Tummers B, Burg SH. High-risk human papillomavirus targets crossroads in immune signaling. Viruses 7(5), 2485-2506 (2015).
49. Zhao J, He S, Minassian A, Li J, Feng P. Recent advances on viral manipulation of NF-kappaB signaling pathway. Curr. Opin. Virol. 15, 103-111 (2015).
50. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr. Opin. Virol. 1(6), 476-486 (2011).
51. Karim R, Meyers C, Backendorf C et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 6(3), e17848 (2011).
52. Reiser J, Hurst J, Voges M et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85(21), 11372-11380 (2011).
53. Hasan UA, Zannetti C, Parroche P et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 210(7), 1369-1387 (2013).
54. Sunthamala N, Thierry F, Teissier S et al. E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-kappa transcription in keratinocytes. PLoS ONE 9(3), e91473 (2014).
55. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12(13), 2061-2072 (1998).
56. Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Res. 21(1), 116-130 (2011).
57. Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: links and trade-offs. Trends Immunol. 35(9), 429-435 (2014).
58. Nakahara T, Tanaka K, Ohno SI, Egawa N, Yugawa T, Kiyono T. Activation of NFkappaB by human papillomavirus 16 E1 limits E1-dependent viral replication through degradation of E1. J. Virol. 89(9), 5040-5059 (2015).
59. Fontaine V, Van Der Meijden E, De Graaf J, Ter Schegget J, Struyk L. A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 272(1), 40-49 (2000).
60. Lace MJ, Anson JR, Haugen TH, Dierdorff JM, Turek LP. Interferon treatment of human keratinocytes harboring extrachromosomal, persistent HPV-16 plasmid genomes induces de novo viral integration. Carcinogenesis 36(1), 151-159 (2015).
61. Pett MR, Herdman MT, Palmer RD et al. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl Acad. Sci. USA 103(10), 3822-3827 (2006).
62. Forero A, Giacobbi NS, Mccormick KD et al. Simian virus 40 large T antigen induces IFN-stimulated genes through ATR kinase. J. Immunol. 192(12), 5933-5942 (2014).
63. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J. 27(24), 3311-3321 (2008).
64. Rivas C, Aaronson SA, Munoz-Fontela C. Dual role of p53 in innate antiviral immunity. Viruses 2(1), 298-313 (2010).
65. Hong S, Mehta KP, Laimins LA. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 85(18), 9486-9494 (2011).
66. Barnard P, Mcmillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-Alpha. Virology 259(2), 305-313 (1999).
67. Hong S, Laimins LA. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog. 9(4), e1003295 (2013).
68. Lace MJ, Anson JR, Klingelhutz AJ et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis 30(8), 1336-1344 (2009).
69. Lace MJ, Anson JR, Haugen TH, Turek LP. Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes. Virology 399(2), 270-279 (2010).
70. Muto V, Stellacci E, Lamberti AG et al. Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes. J. Virol. 85(10), 5070-5080 (2011).
71. Maarifi G, Chelbi-Alix MK, Nisole S. PML control of cytokine signaling. Cytokine Growth Factor Rev. 25(5), 551-561 (2014).
72. Sahin U, Lallemand-Breitenbach V, De The H. PML nuclear bodies: Regulation, function and therapeutic perspectives. J. Pathol. 234(3), 289-291 (2014).
73. Day PM, Baker CC, Lowy DR, Schiller JT. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl Acad. Sci. USA 101(39), 14252-14257 (2004).
74. Stepp WH, Meyers JM, Mcbride AA. Sp100 provides intrinsic immunity against human papillomavirus infection. mBio 4(6), e00845-e00813 (2013).
75. Kivipold P, Vosa L, Ustav M, Kurg R. DAXX modulates human papillomavirus early gene expression and genome replication in U2OS cells. Virol. J. 12, 104 (2015).
76. Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT. Human papillomavirus DNA replication compartments in a transient DNA replication system. J. Virol. 73(2), 1001-1009 (1999).
77. Nakahara T, Lambert PF. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology 366(2), 316-329 (2007).
78. Stanley MA. Genital human papillomavirus infections: current and prospective therapies. J. Gen. Virol. 93(Pt 4), 681-691 (2012).
79. De Oliveira DE, Ballon G, Cesarman E. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol. 18(6), 248-257 (2010).
80. Chan JK, Greene WC. Dynamic roles for NF-kappaB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol. Rev. 246(1), 286-310 (2012).